Operative complications and early mortality after induction therapy for lung cancer

Venuta, Federico; Anile, Marco; Diso, Daniele; Ibrahim, Mohsen; Giacomo, Tiziano De; Rolla, M.; Liparulo, Valeria; Coloni, Giorgio F.

doi:10.1016/j.ejcts.2007.01.017

Cited by 57 publications

(51 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Risk of induction chemotherapy in surgery with an extent of less than pneumonectomy Despite the absence of randomised trials having as end-point the impact of chemotherapy on the post-operative outcome of resections less than pneumonectomy, recent evidence resulting from retrospective and prospective studies [249][250][251][252][253][254] has shown acceptable morbidity and mortality rates in selected patients.…”

Section: Chemo-radiotherapy In Lung Cancermentioning

confidence: 99%

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)

Brunelli¹,

Charloux²,

Bolliger³

et al. 2009

Eur Respir J

766

550

View full text Add to dashboard Cite

A collaboration of multidisciplinary experts on the functional evaluation of lung cancer patients has been facilitated by the European Respiratory Society (ERS) and the European Society of Thoracic Surgery (ESTS), in order to draw up recommendations and provide clinicians with clear, up-to-date guidelines on fitness for surgery and chemo-radiotherapy.The subject was divided into different topics, which were then assigned to at least two experts. The authors searched the literature according to their own strategies, with no central literature review being performed. The draft reports written by the experts on each topic were reviewed, discussed and voted on by the entire expert panel. The evidence supporting each recommendation was summarised, and graded as described by the Scottish Intercollegiate Guidelines Network Grading Review Group. Clinical practice guidelines were generated and finalised in a functional algorithm for risk stratification of the lung resection candidates, emphasising cardiological evaluation, forced expiratory volume in 1 s, systematic carbon monoxide lung diffusion capacity and exercise testing.Contrary to lung resection, for which the scientific evidences are more robust, we were unable to recommend any specific test, cut-off value, or algorithm before chemo-radiotherapy due to the lack of data. We recommend that lung cancer patients should be managed in specialised settings by multidisciplinary teams.

show abstract

Section: Chemo-radiotherapy In Lung Cancermentioning

confidence: 99%

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)

Brunelli¹,

Charloux²,

Bolliger³

et al. 2009

Eur Respir J

766

550

View full text Add to dashboard Cite

show abstract

“…Hino (50) showed that octogenarians with postoperative morbidity had significantly poorer prognosis than those without it. A number of risk factors for developing postoperative morbidity have been reported: congestive heart failure, myocardial infarction, male gender, type of operative procedure, extended lymph node dissection, FEV 1 of 40% or less, smoking status, stroke (3,26,27,42) and administration of induction therapy (51). For all these reasons, a "customized" preoperative assessment to identify physiological or pathological frailty should be encouraged since standard tools may be less reliable.…”

Section: General Considerationsmentioning

confidence: 99%

Lung cancer in elderly patients

et al. 2016

Self Cite

View full text Add to dashboard Cite

“…8 Similarly, Venuta et al observed a mortality rate of 12.5% (4/32) for patients who received neoadjuvant therapy and concluded that pneumonectomy should only be performed in carefully selected patients. 9 However, Alan et al report a low postoperative mortality rate of 5.6% and conclude that there is no significant increase in postoperative mortality after pneumonectomy in those who received neoadjuvant chemotherapy. 10 Similarly, Ng et al did not observe any significant difference in postoperative mortality between the group that underwent neoadjuvant therapy (with no mortalities out of 17 patients) and the group that did not receive neoadjuvant therapy.…”

Section: Resultsmentioning

confidence: 99%

Survival After Pneumonectomy for Stage III Non-small Cell Lung Cancer

Saha

Kalathia²,

Ferraris³

et al. 2011

Chest

View full text Add to dashboard Cite

Objectives: Stage III non-small cell lung cancer (NSCLC) has a poor prognosis. Reports suggest that five-year survival after current treatment is between 14 to 24 percent. The purpose of this retrospective study was to investigate the morbidity and mortality of patients diagnosed with stage III NSCLC and treated with pneumonectomy at the University of Kentucky Medical Center in Lexington, KY. Methods: We reviewed the medical record and tumor registry follow-up data on 100 consecutive patients who underwent pneumonectomy for lung cancer at the University of Kentucky. Results: We identified thirty-six patients in stage III who underwent pneumonectomy. Ten patients had surgery only, eight patients received adjuvant chemotherapy, and eighteen patients received neoadjuvant therapy. There was one surgical death in this series. Mean follow-up was 2.9 years. One-, three-, and five-year survival was 66%, 38%, and 38%, respectively. Five-year survival for the group with adjuvant therapy was 60%. Conclusion: Most lung cancer patients present with advanced disease and the prognosis remains poor. Our experience indicates resection offers an above average chance of long-term survival when supplemented with neoadjuvant and/or adjuvant therapy.

show abstract

Operative complications and early mortality after induction therapy for lung cancer

Abstract: Induction therapy seems to be associated with an increased incidence of air leakage; the risk of other complications is acceptable. Pneumonectomy is associated with an increased risk of mortality and should be performed in selected patients.

Cited by 57 publications

References 20 publications

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)

Lung cancer in elderly patients

Survival After Pneumonectomy for Stage III Non-small Cell Lung Cancer

Contact Info

Product

Resources

About